Biotype Dresden produces Swiss cancer screening test

Test should help against „catastrophic mortality rates of lung cancer patients“

The new „4D Lifetest Lung Dx“ evaluates biological characteristics (biomarkers) in blood samples and can work faster and easier than many conventional diagnostic methods, according to MDG. It can non-invasively assess the development of lung cancer at the earliest stage," the announcement states.

Thus, the test represents a groundbreaking advance in combating the catastrophic mortality rates of lung cancer patients.

Today's diagnostic procedures are often unpleasant

these can be avoided under certain circumstances if the early-stage test is negative

.

Fresh tests planned for other types of cancer

And this one order could soon lead to others for the Dresden lab technicians: The Swiss want to further develop their test method so that it can be used to recognise early signs of breast, prostate and bowel cancer. Both partners are also considering developing oncological diagnostics together in the future. The non-genetic screening tests of the Swiss could be combined with the genetic analysis methods of the Saxons in order to increase the hit rate.

The „Molecular Diagnostics Group“ is an association of several medical and biotech companies in Dresden, which the entrepreneur Wilhelm Zörgiebel has brought together. In addition to Biotype, this also includes the laboratory software company „Qualitype“ and the radiopharmaceutical manufacturer „Rotop“.

Source: Oiger, 22 December 2022